

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare launches revolutionary Solo™ mask for obstructive sleep apnea in New Zealand and Australia

Auckland, New Zealand, 16 October 2023 – Fisher & Paykel Healthcare Corporation Limited today announced the launch of the F&P Solo™ mask in New Zealand and Australia for the treatment of obstructive sleep apnea (OSA).

F&P Solo is a world-first AutoFit™ nasal and pillows mask which simplifies the setup process, enabling users to stretch the mask onto the face and adjust it into place with one touch.

“F&P Solo represents a significant step forward in mask innovation,” said Lewis Gradon, Managing Director and Chief Executive Officer for Fisher & Paykel Healthcare. “Our team has been uncompromising in its focus on patient outcomes, and we believe this mask makes the setup and fit process easier than ever. We’ve begun with a market release in New Zealand and Australia, and more markets will follow in the coming months.”

Without conventional straps to undo and pull, the mask reduces overtightening on the face. AutoLock™ technology holds the mask in place with minimal force and dynamically responds to sleep movement and CPAP-therapy pressure.

“Patients can set themselves up without assistance and then easily finetune the mask during nightly use for an optimal fit,” said Andrew Somervell, VP Products and Technology. “Our focus on what’s best for the patient led us here – we sought a result that optimises for both comfort and simplicity, and we believe F&P Solo delivers on this.”

Sales of F&P Solo have commenced in New Zealand and will begin in Australia at the end of October. Launches into Europe, Canada and the United States are set to follow in the coming months.

Nasal and pillows cushions can be bought individually, allowing users to interchange. The headgear is one size, with four different nasal cushion sizes (small, medium, large and wide) and three different pillows cushion sizes (small, medium and large).

The mask is supported by positive clinical trial results:

- 95% of users can set themselves up without assistance¹; and
- 93% of patients rated their experience with the F&P Solo mask as simple or very simple².

References

¹ 79 out of 83 participants can set themselves up without assistance. Defined as orienting the mask on the head/face as intended and achieving an acceptable seal. Internal self-setup trial conducted with 83 participants, naïve to CPAP therapy, in New Zealand in 2022.

² 85 out of 91 participants rated their experience with the F&P Solo Nasal or F&P Solo Pillows masks as simple or very simple. Internal validation study conducted with 91 participants in the United States in 2022.



About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Media & Investor Contacts:

Hayden Brown
Head of Capital Markets & Investor
Relations
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

Dan Adolph
Senior Communications & Investor Relations
Manager
daniel.adolph@fphcare.co.nz
+64 (0) 22 511 4050

Authorised by Lewis Gradon, Managing Director and Chief Executive Officer.